Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-7: belantamab mafodotin + bortezomib + dexamethasone versus daratumumab + bortezomib + dexamethasone in relapsed/refractory multiple myeloma
NL-OMON60381Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Belantamab mafodotin + bortezomib + dexamethasone with Daratumumab + bortezomib + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Nov 2020; status: active, not recruiting.
02
Drugs
belantamab mafodotindaratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60381.